Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Dexamethasone Degradation in Aqueous Medium and Implications for Correction of In Vitro Release from Sustained Release Delivery Systems.

Matter B, Ghaffari A, Bourne D, Wang Y, Choi S, Kompella UB.

AAPS PharmSciTech. 2019 Oct 23;20(8):320. doi: 10.1208/s12249-019-1508-7.

PMID:
31646399
2.

ISOPT Clinical Hot Topic Panel Discussion on Ocular Drug Delivery.

Kompella UB, Domb A, Urtti A, Jayagopal A, Wilson CG, Tang-Liu D.

J Ocul Pharmacol Ther. 2019 Oct;35(8):457-465. doi: 10.1089/jop.2018.0138. Epub 2019 Jun 28.

PMID:
31259643
3.

Albumin-bound nanodiscs as delivery vehicle candidates: Development and characterization.

Damiati S, Scheberl A, Zayni S, Damiati SA, Schuster B, Kompella UB.

Biophys Chem. 2019 Aug;251:106178. doi: 10.1016/j.bpc.2019.106178. Epub 2019 Apr 30.

PMID:
31102749
4.

Ocular Spot Fluorometer Equipped With a Lock-In Amplifier for Measurement of Aqueous Flare.

Sudhir RR, Murthy PP, Tadepalli S, Murugan S, Padmanabhan P, Krishnamurthy A, Dickinson SL, Karthikeyan R, Kompella UB, Srinivas SP.

Transl Vis Sci Technol. 2018 Dec 21;7(6):32. doi: 10.1167/tvst.7.6.32. eCollection 2018 Nov.

5.

Brain Distribution and Metabolism of Flupirtine, a Nonopioid Analgesic Drug with Antiseizure Effects, in Neonatal Rats.

Patil MA, Matter BA, Raol YH, Bourne DWA, Kelley RA, Kompella UB.

Pharmaceutics. 2018 Dec 16;10(4). pii: E281. doi: 10.3390/pharmaceutics10040281.

6.

Targeted delivery of YSA-functionalized and non-functionalized polymeric nanoparticles to injured pulmonary vasculature.

Patil MA, Upadhyay AK, Hernandez-Lagunas L, Good R, Carpenter TC, Sucharov CC, Nozik-Grayck E, Kompella UB.

Artif Cells Nanomed Biotechnol. 2018;46(sup3):S1059-S1066. doi: 10.1080/21691401.2018.1528984. Epub 2018 Nov 19.

7.

Critical role of endoplasmic reticulum stress in chronic endothelial activation-induced visual deficits in tie2-tumor necrosis factor mice.

Lenin R, Nagy PG, Alli S, Rao VR, Clauss MA, Kompella UB, Gangaraju R.

J Cell Biochem. 2018 Nov;119(10):8460-8471. doi: 10.1002/jcb.27072. Epub 2018 Jul 27.

8.

MicroRNA dysregulation in lung injury: the role of the miR-26a/EphA2 axis in regulation of endothelial permeability.

Good RJ, Hernandez-Lagunas L, Allawzi A, Maltzahn JK, Vohwinkel CU, Upadhyay AK, Kompella UB, Birukov KG, Carpenter TC, Sucharov CC, Nozik-Grayck E.

Am J Physiol Lung Cell Mol Physiol. 2018 Oct 1;315(4):L584-L594. doi: 10.1152/ajplung.00073.2017. Epub 2018 Jul 19.

9.

Corneal epithelial permeability to fluorescein in humans by a multi-drop method.

Srinivas SP, Goyal A, Talele DP, Mahadik S, Sudhir RR, Murthy PP, Ranganath S, Kompella UB, Padmanabhan P.

PLoS One. 2018 Jun 19;13(6):e0198831. doi: 10.1371/journal.pone.0198831. eCollection 2018.

10.

Microfluidic Devices for Drug Delivery Systems and Drug Screening.

Damiati S, Kompella UB, Damiati SA, Kodzius R.

Genes (Basel). 2018 Feb 16;9(2). pii: E103. doi: 10.3390/genes9020103. Review.

11.

Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery.

Hartman RR, Kompella UB.

J Ocul Pharmacol Ther. 2018 Jan/Feb;34(1-2):141-153. doi: 10.1089/jop.2017.0121. Epub 2017 Dec 5. Review.

12.

Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery.

Lancina MG 3rd, Singh S, Kompella UB, Husain S, Yang H.

ACS Biomater Sci Eng. 2017 Aug 14;3(8):1861-1868. doi: 10.1021/acsbiomaterials.7b00319. Epub 2017 Jun 9.

13.

Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR.

Muralidharan R, Babu A, Amreddy N, Srivastava A, Chen A, Zhao YD, Kompella UB, Munshi A, Ramesh R.

Mol Cancer Ther. 2017 Aug;16(8):1470-1486. doi: 10.1158/1535-7163.MCT-17-0134. Epub 2017 Jun 1.

14.

Ocular Drug Delivery.

Yavuz B, Kompella UB.

Handb Exp Pharmacol. 2017;242:57-93. doi: 10.1007/164_2016_84.

PMID:
27783270
15.

Penetration of mucoadhesive chitosan-dextran sulfate nanoparticles into the porcine cornea.

Chaiyasan W, Praputbut S, Kompella UB, Srinivas SP, Tiyaboonchai W.

Colloids Surf B Biointerfaces. 2017 Jan 1;149:288-296. doi: 10.1016/j.colsurfb.2016.10.032. Epub 2016 Oct 17.

PMID:
27771493
16.

Retracted: Self-assembled Phenylalanine-α,β-dehydrophenylalanine Nanotubes for Sustained Intravitreal Delivery of a Multi-targeted Tyrosine Kinase Inhibitor.

Panda JJ, Yandrapu S, Kadam RS, Chauhan VS, Kompella UB.

J Control Release. 2016 Sep 10;237:186. doi: 10.1016/j.jconrel.2016.07.039.

17.

Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration.

Muralidharan R, Babu A, Amreddy N, Basalingappa K, Mehta M, Chen A, Zhao YD, Kompella UB, Munshi A, Ramesh R.

J Nanobiotechnology. 2016 Jun 21;14(1):47. doi: 10.1186/s12951-016-0201-1.

18.

Nanoparticle-mediated expression of a Wnt pathway inhibitor ameliorates ocular neovascularization.

Wang Z, Cheng R, Lee K, Tyagi P, Ding L, Kompella UB, Chen J, Xu X, Ma JX.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):855-64. doi: 10.1161/ATVBAHA.114.304627. Epub 2015 Feb 5.

19.

Potential drug delivery approaches for XFS-associated and XFS-associated glaucoma.

Kulkarni SS, Kompella UB.

J Glaucoma. 2014 Oct-Nov;23(8 Suppl 1):S77-9. doi: 10.1097/IJG.0000000000000109. Review.

PMID:
25275914
20.

Freeze-thaw stress of Alhydrogel ® alone is sufficient to reduce the immunogenicity of a recombinant hepatitis B vaccine containing native antigen.

Clapp T, Munks MW, Trivedi R, Kompella UB, Braun LJ.

Vaccine. 2014 Jun 24;32(30):3765-71. doi: 10.1016/j.vaccine.2014.05.037. Epub 2014 May 20.

PMID:
24856785
21.

Drug and gene delivery to the back of the eye: from bench to bedside.

Rowe-Rendleman CL, Durazo SA, Kompella UB, Rittenhouse KD, Di Polo A, Weiner AL, Grossniklaus HE, Naash MI, Lewin AS, Horsager A, Edelhauser HF.

Invest Ophthalmol Vis Sci. 2014 Apr 28;55(4):2714-30. doi: 10.1167/iovs.13-13707. Review. No abstract available.

22.

Role of MMP-9 in the breakdown of barrier integrity of the corneal endothelium in response to TNF-α.

Rajashekhar G, Shivanna M, Kompella UB, Wang Y, Srinivas SP.

Exp Eye Res. 2014 May;122:77-85. doi: 10.1016/j.exer.2014.03.004. Epub 2014 Mar 22.

PMID:
24667088
23.

The safety, pharmacokinetics, and efficacy of intraocular celecoxib.

Kim SJ, Toma H, Shah R, Kompella UB, Vooturi SK, Sheng J.

Invest Ophthalmol Vis Sci. 2014 Mar 10;55(3):1409-18. doi: 10.1167/iovs.13-13667.

24.

Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab.

Yandrapu SK, Upadhyay AK, Petrash JM, Kompella UB.

Mol Pharm. 2013 Dec 2;10(12):4676-86. doi: 10.1021/mp400487f. Epub 2013 Nov 12.

25.

Self-assembled phenylalanine-α,β-dehydrophenylalanine nanotubes for sustained intravitreal delivery of a multi-targeted tyrosine kinase inhibitor.

Panda JJ, Yandrapu S, Kadam RS, Chauhan VS, Kompella UB.

J Control Release. 2013 Dec 28;172(3):1151-60. doi: 10.1016/j.jconrel.2013.09.016. Epub 2013 Sep 25. Retraction in: J Control Release. 2016 Sep 10;237:186.

26.

pH shift assembly of adenoviral serotype 5 capsid protein nanosystems for enhanced delivery of nanoparticles, proteins and nucleic acids.

Rao VR, Upadhyay AK, Kompella UB.

J Control Release. 2013 Nov 28;172(1):341-350. doi: 10.1016/j.jconrel.2013.08.023. Epub 2013 Sep 1.

PMID:
24004886
27.

Pirfenidone nanoparticles improve corneal wound healing and prevent scarring following alkali burn.

Chowdhury S, Guha R, Trivedi R, Kompella UB, Konar A, Hazra S.

PLoS One. 2013 Aug 5;8(8):e70528. doi: 10.1371/journal.pone.0070528. Print 2013.

28.

Polychromatic angiography for the assessment of VEGF-induced BRB dysfunction in the rabbit retina.

Tari SR, Youssif M, Samson CM, Harris RL, Lin CM, Kompella UB, Antonetti DA, Barile GR.

Invest Ophthalmol Vis Sci. 2013 Aug 15;54(8):5550-8. doi: 10.1167/iovs.13-12144.

PMID:
23882687
29.

Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab.

Tyagi P, Barros M, Stansbury JW, Kompella UB.

Mol Pharm. 2013 Aug 5;10(8):2858-67. doi: 10.1021/mp300716t. Epub 2013 Jul 8.

30.
31.

Withaferin A effectively targets soluble vimentin in the glaucoma filtration surgical model of fibrosis.

Bargagna-Mohan P, Deokule SP, Thompson K, Wizeman J, Srinivasan C, Vooturi S, Kompella UB, Mohan R.

PLoS One. 2013 May 8;8(5):e63881. doi: 10.1371/journal.pone.0063881. Print 2013.

32.

Biosynthesis, characterization, and efficacy in retinal degenerative diseases of lens epithelium-derived growth factor fragment (LEDGF1-326), a novel therapeutic protein.

Baid R, Upadhyay AK, Shinohara T, Kompella UB.

J Biol Chem. 2013 Jun 14;288(24):17372-83. doi: 10.1074/jbc.M112.441618. Epub 2013 May 2.

33.

Hypoxia alters ocular drug transporter expression and activity in rat and calf models: implications for drug delivery.

Kadam RS, Ramamoorthy P, LaFlamme DJ, McKinsey TA, Kompella UB.

Mol Pharm. 2013 Jun 3;10(6):2350-61. doi: 10.1021/mp3007133. Epub 2013 May 22. Retraction in: Mol Pharm. 2015 Jul 6;12(7):2559.

34.

Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.

Kompella UB, Amrite AC, Pacha Ravi R, Durazo SA.

Prog Retin Eye Res. 2013 Sep;36:172-98. doi: 10.1016/j.preteyeres.2013.04.001. Epub 2013 Apr 17. Review.

35.

Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose.

Dhanda DS, Tyagi P, Mirvish SS, Kompella UB.

J Control Release. 2013 Jun 28;168(3):239-50. doi: 10.1016/j.jconrel.2013.03.027. Epub 2013 Apr 4.

PMID:
23562638
36.

Nanotechnology and drug delivery.

Kompella UB.

J Ocul Pharmacol Ther. 2013 Mar;29(2):89. doi: 10.1089/jop.2013.1504. No abstract available.

PMID:
23485089
37.

Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration.

Luo L, Zhang X, Hirano Y, Tyagi P, Barabás P, Uehara H, Miya TR, Singh N, Archer B, Qazi Y, Jackman K, Das SK, Olsen T, Chennamaneni SR, Stagg BC, Ahmed F, Emerson L, Zygmunt K, Whitaker R, Mamalis C, Huang W, Gao G, Srinivas SP, Krizaj D, Baffi J, Ambati J, Kompella UB, Ambati BK.

ACS Nano. 2013 Apr 23;7(4):3264-75. doi: 10.1021/nn305958y. Epub 2013 Mar 20.

38.

Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells.

Baltazar GC, Guha S, Lu W, Lim J, Boesze-Battaglia K, Laties AM, Tyagi P, Kompella UB, Mitchell CH.

PLoS One. 2012;7(12):e49635. doi: 10.1371/journal.pone.0049635. Epub 2012 Dec 18.

39.

Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye.

Yandrapu S, Kompella UB.

J Ocul Pharmacol Ther. 2013 Mar;29(2):236-48. doi: 10.1089/jop.2012.0210. Epub 2012 Dec 20.

40.

Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice.

Trivedi R, Redente EF, Thakur A, Riches DW, Kompella UB.

Nanotechnology. 2012 Dec 21;23(50):505101. doi: 10.1088/0957-4484/23/50/505101. Epub 2012 Nov 27.

PMID:
23186914
41.
42.

Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry.

Tyagi P, Kadam RS, Kompella UB.

PLoS One. 2012;7(10):e48188. doi: 10.1371/journal.pone.0048188. Epub 2012 Oct 31.

43.

Pigmented-MDCK (P-MDCK) cell line with tunable melanin expression: an in vitro model for the outer blood-retinal barrier.

Kadam RS, Scheinman RI, Kompella UB.

Mol Pharm. 2012 Nov 5;9(11):3228-35. doi: 10.1021/mp300305f. Epub 2012 Oct 15.

44.

Transporter targeted gatifloxacin prodrugs: synthesis, permeability, and topical ocular delivery.

Vooturi SK, Kadam RS, Kompella UB.

Mol Pharm. 2012 Nov 5;9(11):3136-46. doi: 10.1021/mp300245r. Epub 2012 Oct 11.

45.
46.

Silibinin, dexamethasone, and doxycycline as potential therapeutic agents for treating vesicant-inflicted ocular injuries.

Tewari-Singh N, Jain AK, Inturi S, Ammar DA, Agarwal C, Tyagi P, Kompella UB, Enzenauer RW, Petrash JM, Agarwal R.

Toxicol Appl Pharmacol. 2012 Oct 1;264(1):23-31. doi: 10.1016/j.taap.2012.07.014. Epub 2012 Jul 24.

47.

RETRACTED: Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide.

Kadam RS, Tyagi P, Edelhauser HF, Kompella UB.

Int J Pharm. 2012 Sep 15;434(1-2):140-7. doi: 10.1016/j.ijpharm.2012.05.025. Epub 2012 May 23.

48.

Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.

Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, Kompella UB, Le M, Predhomme JA, Rower JE, Sidhom MS.

Br J Clin Pharmacol. 2013 Jan;75(1):217-26. doi: 10.1111/j.1365-2125.2012.04343.x.

49.

Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance.

Kadam RS, Bourne DW, Kompella UB.

Drug Metab Dispos. 2012 Jul;40(7):1380-8. doi: 10.1124/dmd.112.044925. Epub 2012 Apr 12.

50.

Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization.

Qazi Y, Stagg B, Singh N, Singh S, Zhang X, Luo L, Simonis J, Kompella UB, Ambati BK.

Invest Ophthalmol Vis Sci. 2012 May 14;53(6):2837-44. doi: 10.1167/iovs.11-9139.

Supplemental Content

Loading ...
Support Center